CARDIOMYOPATHY, SECONDARY
Clinical trials for CARDIOMYOPATHY, SECONDARY explained in plain language.
Never miss a new study
Get alerted when new CARDIOMYOPATHY, SECONDARY trials appear
Sign up with your email to follow new studies for CARDIOMYOPATHY, SECONDARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy targets heart damage in rare neurological disease
Disease control OngoingThis early-stage study tests a gene therapy called LX2006 in 8 people with Friedreich's ataxia who also have heart muscle disease. The treatment delivers a working copy of the frataxin gene to heart cells through a single IV infusion. Researchers will monitor safety and heart fun…
Matched conditions: CARDIOMYOPATHY, SECONDARY
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 17, 2026 10:38 UTC
-
Can a simple risk score stop pacemakers from weakening the heart?
Knowledge-focused OngoingThis study looks at 4,500 people with pacemakers or similar heart devices to find out who is most likely to develop a condition where the heart weakens over time. Researchers will use routine medical and device data to create a risk score that helps doctors choose the best pacing…
Matched conditions: CARDIOMYOPATHY, SECONDARY
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated May 11, 2026 20:40 UTC